Press
Yemaachi News
May 25, 2022
As one of Ghana's only labs equipped for molecular analysis, Bediako's team have tasked themselves with collecting data they believe will advance the development of medicine for cancer patients throughout the continent and diaspora
March 21, 2022
Yemaachi Biotech announced today the close of a $3 million seed round to advance its mission of diversifying precision oncology globally. V8 Capital led the round, with LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital and Ethan Perlstein also participating.
February 22, 2022
GenomeWeb covers Yemaachi's launch of its Sheba HPV Test, a convenient discreet way for women to screen themselves for HPV and assess their risk for cervical cancer.
January 27, 2022
Yemaachi Biotech's Heritage Study is the first of its kind to compare immune responses to the same vaccine in both African and European populations, and could provide important insights into how vaccines can be optimally designed for African people
January 27, 2022
Yemaachi Launches Sheba HPV Test for screening of high risk HPV variants that cause cervical cancer
Yemaachi marks cervical cancer awareness month with the launch of the Sheba HPV Test, a cervical cancer screening tool that features at-home sampling and high risk HPV DNA detection.
November 3, 2021
GenomeWeb covers Yemaachi's collaboration with cancer liquid biopsy firm Lucence to document and characterize the genomics of breast cancer in women of African descent.
October 26, 2021
PALO ALTO, Calif. & ACCRA, Ghana--(BUSINESS WIRE)--Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, announced today that they are collaborating on a study to better characterize and understand the genomics of breast cancer in women of African descent.
August 31, 2021
Tech Crunch profiles Yemaachi Biotech and the other 14 African Startups that were selected to be a part of Y Combinator's summer batch of 2021.
May 30, 2021
The Holistic Drug Discovery and Development (H3D) Centre at the University of Cape Town (UCT) has entered into a strategic partnership with Yemaachi Biotech, to exploit African genetic diversity by identifying new therapies and platforms that optimize cancer treatments for African patient populations.